AST expansion Leverage CirrusDx’s antimicrobial susceptibility testing capabilities, including recent gepotidacin (Blujepa) AST launch, to target UTI and resistant infection markets and cross-sell to hospitals seeking expanded pathogen profiling and tailored therapy.

Integrated diagnostics Position CirrusDx as a one-stop solution that combines molecular techniques with culture to deliver actionable results on pathogens, growth dynamics, and antibiotic responses, appealing to labs and health systems aiming to shorten turnaround times and improve treatment decisions.

Women’s health focus Highlight specialization in women’s health infections (UTI, vaginitis, STI, respiratory, wound) to target OB/GYN clinics, women's health networks, and hospital systems prioritizing outcomes in gender-specific care.

Clinical collaboration Emphasize dedicated clinical team and responsive service with real-person support to differentiate from competitors and promote long-term lab partnerships with health systems seeking reliable consultative testing and rapid answers.

Financial potential Target mid-market hospitals and regional health systems with CLIA-certified, faster turnaround testing and actionable results to drive value-based care, given CirrusDx’s revenue scale and room to grow within infections testing and resistance profiling.